Food Hypersensitivity Clinical Trial
Official title:
An Exploratory Pilot Study Evaluating the Correlation Between Conjunctival Allergen Challenge (CAC) Response to Dissolved Food Allergen and Previously Performed Oral Escalating Dose Food Challenge Response
The objective of this study is to compare the ocular response to CAC (using food allergen sensitive patients) to the systemic response of a previously performed oral food allergen challenge in the same subjects. This study will investigate the potential utility of CAC as a predictive tool for identifying patient response to food allergen challenge and maximum tolerated dose.
Patients usually discover they have food allergies after consuming a given food and
experiencing a subsequent allergic reaction. The majority of patients (75%) will then consult
a food allergist for formal diagnosis and treatment information.1 With respect to patient
quality of life, there is tremendous benefit in having a confirmed diagnosis of food allergy
as often patients are unsure of the source of their reaction outside the office. Allergists
will conduct Skin Prick Test (SPT) and assess serum specific IgE levels to screen for
specific food protein sensitivities. However, a positive response in SPT and specific IgE
will confirm only sensitivity, and in more than 70% of cases patients that respond positively
to SPT and specific IgE testing will NOT manifest an allergic response to food consumption.2
To address this issue, most food allergists will recommend an oral food challenge in a
controlled setting to confirm the allergic response from consuming the suspected foods. The
oral food challenge (OFC) consists of consuming escalating levels of the suspect food,
(usually mixed in applesauce or controlled baked goods), until either a reaction manifests or
until the challenge is complete with no reaction. The food challenge process poses
significant risk to the patient. In 5% of cases, the patient experiences a severe allergic
response which requires the use of epinephrine.2,3 These responses typically consist of
severe reactions in GI or respiratory and arise from challenging patients with higher doses
of food allergen then is necessary to prove a mild allergic response. The reason an allergist
would give an increased dose that the patient reacts to with severity results from
misdiagnosing the mild forms of the reaction during the titrated challenge. It is this
shortcoming in diagnosis that could be addressed by identifying high-risk patient populations
through conjunctival allergen challenge and through the development of additional objective
diagnostic endpoints.
We hypothesize that conjunctival allergen challenge (CAC) may be able to predict which
patients are likely to experience an adverse event during a food allergen challenge. The
appearance of severe ocular response following CAC (level II on a 0-2 Scale) has been shown
to correlate well with a positive food response during escalating food challenge, and
represented a better predictor of food allergen than skin test and serum specific IgE
combined.4 We hypothesize that the severity of the ocular response to CAC titration, or the
appearance of related non-ocular signs and symptoms of systemic response to CAC (itchy
palate, wheezing, FEV1 reduction) could correlate with the likelihood of experiencing a
severe adverse event during food challenge. In order to mitigate the occurrence of severe
adverse events during food challenge, and to determine if the CAC response can serve as a
useful tool for informing the clinician of anticipated patient response patterns to oral food
allergen challenge, we will perform CAC titration on a population of food allergy patients
that previously underwent oral food escalating challenge. Any patterns in CAC response will
be compared to historical food allergen reactivity and occurrence of severe adverse responses
to evaluate the potential of the CAC as a predictive tool that could add value to the oral
food challenge model.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01904604 -
Peanut Epicutaneous Phase II Immunotherapy Clinical Trial
|
Phase 2 | |
Enrolling by invitation |
NCT04885959 -
The Effects of Traditional Asian Diet on Gut Microbiome and Metabolome in Healthy Volunteers and Pregnancy on Subsequent Infant's Allergy Development
|
N/A | |
Recruiting |
NCT03974555 -
Epidemiological Investigation and Cohort Study on Food Allergy in Children Aged 3 to 6 Years in Wenzhou and Taizhou Urban Areas
|
||
Recruiting |
NCT05177744 -
Toxicity of Micro and Nano Plastics Combined With Environmental Contaminants on the Risk of Allergic Disease
|
||
Completed |
NCT01420705 -
Bacille Calmette-Guérin (BCG) Vaccine and Atopy
|
N/A | |
Completed |
NCT00850668 -
Peanut Allergy Vaccine Study in Healthy and Peanut-allergic Adults
|
Phase 1 | |
Withdrawn |
NCT00736112 -
Food Allergy - Tubes - Adenoids (FATA) Trial
|
N/A | |
Active, not recruiting |
NCT00298337 -
Use of Probiotic Bacteria in Prevention of Allergic Disease in Children 1999-2008
|
Phase 2/Phase 3 | |
Completed |
NCT00461097 -
Oral Immunotherapy for Childhood Egg Allergy
|
Phase 2 | |
Completed |
NCT02606721 -
Food Allergy Challenge Diagnostic Study
|
||
Active, not recruiting |
NCT02457416 -
Take Away Food Allergy; Inducing Tolerance in Children Allergic to Peanut
|
N/A | |
Completed |
NCT02825069 -
Study on the Induction of Food Tolerance in Babies
|
N/A | |
Completed |
NCT02350660 -
Oral Immunotherapy for Peanut and Mammalian Meat Allergies
|
N/A | |
Completed |
NCT01084174 -
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy
|
Phase 1/Phase 2 | |
Completed |
NCT00597675 -
Oral Immunotherapy for Peanut Allergy (PMIT)
|
Phase 2 | |
Completed |
NCT00932828 -
Determining the Efficacy and Value of Immunotherapy on the Likelihood of Peanut Tolerance: The DEVIL Study
|
Phase 2 | |
Completed |
NCT01373242 -
Sublingual Immunotherapy for Peanut Allergy and Induction of Tolerance
|
Phase 1/Phase 2 | |
Completed |
NCT00578656 -
An Interventional Study of Milk Allergy
|
Phase 0 | |
Completed |
NCT00356174 -
An Observational Study of Childhood Food Allergy
|
N/A | |
Completed |
NCT02304991 -
FARE Peanut SLIT and Early Tolerance Induction
|
Phase 2 |